{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:54:54Z","timestamp":1789584894035,"version":"build-2803163510"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12149-025-02072-1","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T10:58:49Z","timestamp":1751108329000},"page":"755-773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of radiolabeled somatostatin analogs (DOTATATE, DOTANOC, and DOTATOC) in somatostatin receptor (SSTR) imaging for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a narrative literature review"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8310-1242","authenticated-orcid":false,"given":"Ryan Reinardi","family":"Wijaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendra","family":"Budiawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basuki","family":"Hidayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Budi","family":"Darmawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trias","family":"Nugrahadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achmad Hussein Sundawa","family":"Kartamihardja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"issue":"7","key":"2072_CR1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844\u201360.","journal-title":"Ann Oncol"},{"issue":"10","key":"2072_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335.","journal-title":"JAMA Oncol"},{"issue":"10","key":"2072_CR3","doi-asserted-by":"publisher","first-page":"E398","DOI":"10.1503\/cmaj.160771","volume":"189","author":"MJ Raphael","year":"2017","unstructured":"Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. Can Med Assoc J. 2017;189(10):E398-404.","journal-title":"Can Med Assoc J"},{"issue":"6","key":"2072_CR4","doi-asserted-by":"publisher","first-page":"986","DOI":"10.2967\/jnumed.123.265603","volume":"64","author":"JL Urbain","year":"2023","unstructured":"Urbain JL, Scott AM, Lee ST, Buscombe J, Weston C, Hatazawa J, et al. Theranostic radiopharmaceuticals: a universal challenging educational paradigm in nuclear medicine. J Nucl Med. 2023;64(6):986\u201391.","journal-title":"J Nucl Med"},{"issue":"2","key":"2072_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182\u20138.","journal-title":"Histopathology"},{"issue":"3","key":"2072_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4240\/wjgs.v13.i3.231","volume":"13","author":"CJ Fernandez","year":"2021","unstructured":"Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: a clinical snapshot. World J Gastrointest Surg. 2021;13(3):231\u201355.","journal-title":"World J Gastrointest Surg"},{"issue":"7275","key":"2072_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0140-6736(63)90951-6","volume":"1","author":"E Williams","year":"1963","unstructured":"Williams E, Sandler M. The classification of carcinoid tumours. Lancet. 1963;1(7275):238\u20139.","journal-title":"Lancet"},{"key":"2072_CR8","unstructured":"O\u2019Toole TJ, Sharma S. Physiology, Somatostatin. 2024."},{"issue":"3","key":"2072_CR9","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.3390\/ijms23031447","volume":"23","author":"O Rogoza","year":"2022","unstructured":"Rogoza O, Megnis K, Kudrjavceva M, Gerina-Berzina A, Rovite V. Role of somatostatin signalling in neuroendocrine tumours. Int J Mol Sci. 2022;23(3):1447.","journal-title":"Int J Mol Sci"},{"issue":"Suppl. 1","key":"2072_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000051852","volume":"62","author":"N Benali","year":"2000","unstructured":"Benali N, Ferjoux G, Puente E, Buscail L, Susini C. Somatostatin receptors. Digestion. 2000;62(Suppl. 1):27\u201332.","journal-title":"Digestion"},{"issue":"5","key":"2072_CR11","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1507\/endocrj.52.605","volume":"52","author":"Y Taniyama","year":"2005","unstructured":"Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S, Sasano H. Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J. 2005;52(5):605\u201311.","journal-title":"Endocr J"},{"issue":"1","key":"2072_CR12","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/ijms25010436","volume":"25","author":"U Kumar","year":"2023","unstructured":"Kumar U. Somatostatin and somatostatin receptors in tumour biology. Int J Mol Sci. 2023;25(1):436.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2072_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/0026-0495(90)90217-Z","volume":"39","author":"J Reubi","year":"1990","unstructured":"Reubi J, Kvols L, Krenning E, Lamberts S. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism. 1990;39(9):78\u201381.","journal-title":"Metabolism"},{"issue":"1","key":"2072_CR14","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1038\/s41598-019-39607-2","volume":"9","author":"R Mai","year":"2019","unstructured":"Mai R, Kaemmerer D, Tr\u00e4ger T, Neubauer E, S\u00e4nger J, Baum RP, et al. Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin. Sci Rep. 2019;9(1):4339.","journal-title":"Sci Rep"},{"key":"2072_CR15","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.dld.2003.11.008","volume":"36","author":"VD Corleto","year":"2004","unstructured":"Corleto VD, Nasoni S, Panzuto F, Cassetta S, Fave GD. Somatostatin receptor subtypes: basic pharmacology and tissue distribution. Dig Liver Dis. 2004;36:S8-16.","journal-title":"Dig Liver Dis"},{"issue":"7","key":"2072_CR16","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.3390\/jcm9072203","volume":"9","author":"MI del Olmo-Garc\u00eda","year":"2020","unstructured":"del Olmo-Garc\u00eda MI, Muros MA, L\u00f3pez-de-la-Torre M, Agudelo M, Bello P, Soriano JM, et al. Prevention and management of hormonal crisis during theragnosis with LU-DOTA-TATE in neuroendocrine tumors. A systematic review and approach proposal. J Clin Med. 2020;9(7):2203.","journal-title":"J Clin Med"},{"issue":"3","key":"2072_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.dld.2009.07.018","volume":"42","author":"V Zamora","year":"2010","unstructured":"Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, et al. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis. 2010;42(3):220\u20135.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"2072_CR18","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/annonc\/mdh216","volume":"15","author":"K \u00d6berg","year":"2004","unstructured":"\u00d6berg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15(6):966\u201373.","journal-title":"Ann Oncol"},{"issue":"2","key":"2072_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.5603\/NMR.2016.0022","volume":"19","author":"J Hankus","year":"2016","unstructured":"Hankus J, Tomaszewska R. Neuroendocrine neoplasms and somatostatin receptor subtypes expression. Nucl Med Rev. 2016;19(2):111\u20137.","journal-title":"Nucl Med Rev"},{"issue":"10","key":"2072_CR20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1369\/0022155419856900","volume":"67","author":"SM Remes","year":"2019","unstructured":"Remes SM, Leijon HL, Vesterinen TJ, Arola JT, Haglund CH. Immunohistochemical expression of somatostatin receptor subtypes in a panel of neuroendocrine neoplasias. J Histochem Cytochem. 2019;67(10):735\u201343.","journal-title":"J Histochem Cytochem"},{"issue":"3","key":"2072_CR21","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1053\/j.gastro.2010.07.002","volume":"139","author":"KE \u00d6berg","year":"2010","unstructured":"\u00d6berg KE, Reubi J, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010;139(3):742-753.e1.","journal-title":"Gastroenterology"},{"issue":"14","key":"2072_CR22","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.2217\/fon.14.139","volume":"10","author":"CB Johnbeck","year":"2014","unstructured":"Johnbeck CB, Knigge U, Kj\u00e6r A. Pet tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10(14):2259\u201377.","journal-title":"Future Oncol"},{"issue":"5","key":"2072_CR23","first-page":"311","volume":"8","author":"E Pauwels","year":"2018","unstructured":"Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands\u2014the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8(5):311\u201331.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"3","key":"2072_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"JC Reubi","year":"2000","unstructured":"Reubi JC, Sch\u00e4r JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med Mol Imaging. 2000;27(3):273\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2072_CR25","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/s00259-006-0317-x","volume":"34","author":"P Antunes","year":"2007","unstructured":"Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34(7):982\u201393.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2072_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4274\/mirt.galenos.2021.37268","volume":"30","author":"S \u00d6zg\u00fcven","year":"2021","unstructured":"\u00d6zg\u00fcven S, Filizo\u011flu N, Kesim S, \u00d6ks\u00fczo\u011flu K, \u015een F, \u00d6ne\u015f T, et al. Physiological biodistribution of 68Ga-DOTA-TATE in normal subjects. Mol Imaging Radionucl Ther. 2021;30(1):39\u201346.","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"6","key":"2072_CR27","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2214\/AJR.14.12588","volume":"203","author":"O Kagna","year":"2014","unstructured":"Kagna O, Pirmisashvili N, Tshori S, Freedman N, Israel O, Krausz Y. Neuroendocrine tumor imaging with 68Ga-DOTA-NOC: physiologic and benign variants. Am J Roentgenol. 2014;203(6):1317\u201323.","journal-title":"Am J Roentgenol"},{"issue":"3","key":"2072_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/ph13030038","volume":"13","author":"U Hennrich","year":"2020","unstructured":"Hennrich U, Bene\u0161ov\u00e1 M. [68Ga]Ga-DOTA-TOC: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging. Pharmaceuticals. 2020;13(3):38.","journal-title":"Pharmaceuticals"},{"issue":"4","key":"2072_CR29","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1159\/000517530","volume":"112","author":"J Yu","year":"2022","unstructured":"Yu J, Cao F, Zhao X, Xie Q, Lu M, Li J, et al. Correlation and comparison of somatostatin receptor type 2 immunohistochemical scoring systems with 68Ga-DOTATATE positron emission tomography\/computed tomography imaging in gastroenteropancreatic neuroendocrine neoplasms. Neuroendocrinology. 2022;112(4):358\u201369.","journal-title":"Neuroendocrinology"},{"issue":"7","key":"2072_CR30","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","volume":"19","author":"MH Shah","year":"2021","unstructured":"Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19(7):839\u201368.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"11","key":"2072_CR31","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1007\/s00259-013-2482-z","volume":"40","author":"H Geijer","year":"2013","unstructured":"Geijer H, Breimer LH. Somatostatin receptor PET\/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2013;40(11):1770\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"2072_CR32","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/RLU.0000000000002276","volume":"43","author":"S Singh","year":"2018","unstructured":"Singh S, Poon R, Wong R, Metser U. 68Ga PET imaging in patients with neuroendocrine tumors. Clin Nucl Med. 2018;43(11):802\u201310.","journal-title":"Clin Nucl Med"},{"issue":"8","key":"2072_CR33","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3390\/diagnostics10080598","volume":"10","author":"M Bauckneht","year":"2020","unstructured":"Bauckneht M, Albano D, Annunziata S, Santo G, Guglielmo P, Frantellizzi V, et al. Somatostatin receptor PET\/CT imaging for the detection and staging of pancreatic NET: a systematic review and meta-analysis. Diagnostics. 2020;10(8):598.","journal-title":"Diagnostics"},{"issue":"11","key":"2072_CR34","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.3390\/cimb44110373","volume":"44","author":"G Poletto","year":"2022","unstructured":"Poletto G, Cecchin D, Sperti S, Filippi L, Realdon N, Evangelista L. Head-to-head comparison between peptide-based radiopharmaceutical for PET and SPECT in the evaluation of neuroendocrine tumors: a systematic review. Curr Issues Mol Biol. 2022;44(11):5516\u201330.","journal-title":"Curr Issues Mol Biol"},{"issue":"4","key":"2072_CR35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/0284185113496679","volume":"55","author":"J Yang","year":"2014","unstructured":"Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta radiol. 2014;55(4):389\u201398.","journal-title":"Acta radiol"},{"issue":"3","key":"2072_CR36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2967\/jnumed.112.111724","volume":"54","author":"D Wild","year":"2013","unstructured":"Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET\/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54(3):364\u201372.","journal-title":"J Nucl Med"},{"issue":"8","key":"2072_CR37","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00259-012-2123-y","volume":"39","author":"L Kabasakal","year":"2012","unstructured":"Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET\/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(8):1271\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"2072_CR38","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","volume":"52","author":"TD Poeppel","year":"2011","unstructured":"Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52(12):1864\u201370.","journal-title":"J Nucl Med"},{"issue":"6","key":"2072_CR39","doi-asserted-by":"publisher","first-page":"872","DOI":"10.2967\/jnumed.115.165803","volume":"57","author":"SA Deppen","year":"2016","unstructured":"Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, et al. 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J Nucl Med. 2016;57(6):872\u20138.","journal-title":"J Nucl Med"},{"issue":"1","key":"2072_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2967\/jnumed.115.166017","volume":"57","author":"E Skoura","year":"2016","unstructured":"Skoura E, Michopoulou S, Mohmaduvesh M, Panagiotidis E, Al Harbi M, Toumpanakis C, et al. The impact of 68Ga-DOTATATE PET\/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom. J Nucl Med. 2016;57(1):34\u201340.","journal-title":"J Nucl Med"},{"issue":"6","key":"2072_CR41","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.2015.64.0987","volume":"34","author":"SM Sadowski","year":"2016","unstructured":"Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, et al. Prospective study of 68Ga-DOTATATE positron emission tomography\/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. 2016;34(6):588\u201396.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2072_CR42","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3390\/cancers15020513","volume":"15","author":"A Lugat","year":"2023","unstructured":"Lugat A, Frampas \u00c9, Touchefeu Y, Miralli\u00e9 \u00c9, Le BM, Senellart H, et al. Prospective multicentric assessment of 68Ga-DOTANOC PET\/CT in grade 1\u20132 GEP-NET. Cancers (Basel). 2023;15(2):513.","journal-title":"Cancers (Basel)"},{"key":"2072_CR43","first-page":"12","volume":"1","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Wang Z, Zhang B, Wu Y, Li G, Wang Z. Comparison of 68Ga-DOTANOC and 18F-FDG PET-CT scans in the evaluation of primary tumors and lymph node metastasis in patients with rectal neuroendocrine tumors. Front Endocrinol (Lausanne). 2021;1:12.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2072_CR44","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1097\/RLU.0b013e31827a216b","volume":"39","author":"N Naswa","year":"2014","unstructured":"Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, et al. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT. Clin Nucl Med. 2014;39(1):e27-34.","journal-title":"Clin Nucl Med"},{"issue":"5","key":"2072_CR45","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2214\/AJR.11.7298","volume":"197","author":"N Naswa","year":"2011","unstructured":"Naswa N, Sharma P, Kumar A, Nazar AH, Kumar R, Chumber S, et al. Gallium-68-DOTA-NOC PET\/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. Am J Roentgenol. 2011;197(5):1221\u20138.","journal-title":"Am J Roentgenol"},{"issue":"9","key":"2072_CR46","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.2967\/jnumed.117.191197","volume":"58","author":"MM Graham","year":"2017","unstructured":"Graham MM, Gu X, Ginader T, Breheny P, Sunderland JJ. 68Ga-DOTATOC imaging of neuroendocrine tumors: a systematic review and metaanalysis. J Nucl Med. 2017;58(9):1452\u20138.","journal-title":"J Nucl Med"},{"issue":"7","key":"2072_CR47","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1097\/MPA.0000000000001356","volume":"48","author":"H Chan","year":"2019","unstructured":"Chan H, Moseley C, Zhang L, Bergsland EK, Pampaloni MH, Van Loon K, et al. Correlation of DOTATOC uptake and pathologic grade in neuroendocrine tumors. Pancreas. 2019;48(7):948\u201352.","journal-title":"Pancreas"},{"key":"2072_CR48","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/978-3-642-27994-2_18","volume":"194","author":"TD Poeppel","year":"2013","unstructured":"Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. Differential uptake of 68Ga-DOTATOC and 68Ga-DOTATATE in PET\/CT of gastroenteropancreatic neuroendocrine tumors. Recent Results Cancer Res. 2013;194:353\u201371.","journal-title":"Recent Results Cancer Res"},{"issue":"2","key":"2072_CR49","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2967\/jnumed.113.126177","volume":"55","author":"I Velikyan","year":"2014","unstructured":"Velikyan I, Sundin A, S\u00f6rensen J, Lubberink M, Sandstr\u00f6m M, Garske-Rom\u00e1n U, et al. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med. 2014;55(2):204\u201310.","journal-title":"J Nucl Med"},{"key":"2072_CR50","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/978-3-642-27994-2_30","volume":"194","author":"C Schuchardt","year":"2013","unstructured":"Schuchardt C, Kulkarni HR, Prasad V, Zachert C, M\u00fcller D, Baum RP. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using 177Lu-DOTATATE, 177Lu-DOTANOC, and 177Lu-DOTATOC. Recent Results Cancer Res. 2013;194:519\u201336.","journal-title":"Recent Results Cancer Res"},{"key":"2072_CR51","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/978-3-031-33533-4_34","volume-title":"Beyond becquerel and biology to precision radiomolecular oncology: festschrift in honor of Richard P Baum","author":"MV Todorovi\u0107-Tirnani\u0107","year":"2024","unstructured":"Todorovi\u0107-Tirnani\u0107 MV, van Echteld CJA, Gaji\u0107 MM, Baum RP. Uptake of 68Ga-DOTATATE and 68Ga-DOTATOC in primary neuroendocrine tumors, metastases, and normal liver tissue: is there a significant difference? In: Beyond becquerel and biology to precision radiomolecular oncology: festschrift in honor of Richard P Baum. Cham: Springer International Publishing; 2024. p. 337\u201348."},{"key":"2072_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-004-1553-6","author":"F Forrer","year":"2004","unstructured":"Forrer F, Uusij\u00e4rvi H, Waldherr C, Cremonesi M, Bernhardt P, Mueller-Brand J, et al. A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004. https:\/\/doi.org\/10.1007\/s00259-004-1553-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2072_CR53","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/rpd\/ncp107","volume":"135","author":"International Atomic Energy Agency (IAEA)","year":"2009","unstructured":"International Atomic Energy Agency (IAEA). Report of a consultation on justification of patient exposures in medical imaging. Radiat Prot Dosimetry. 2009;135(2):137\u201344.","journal-title":"Radiat Prot Dosimetry"},{"issue":"10","key":"2072_CR54","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2967\/jnumed.113.120600","volume":"54","author":"M Sandstr\u00f6m","year":"2013","unstructured":"Sandstr\u00f6m M, Velikyan I, Garske-Rom\u00e1n U, S\u00f6rensen J, Eriksson B, Granberg D, et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med. 2013;54(10):1755\u20139.","journal-title":"J Nucl Med"},{"issue":"6","key":"2072_CR55","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2967\/jnumed.112.114165","volume":"54","author":"RC Walker","year":"2013","unstructured":"Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M. Measured human dosimetry of 68Ga-DOTATATE. J Nucl Med. 2013;54(6):855\u201360.","journal-title":"J Nucl Med"},{"issue":"05","key":"2072_CR56","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3413\/nukmed-0214","volume":"48","author":"H Hartmann","year":"2009","unstructured":"Hartmann H, Z\u00f6phel K, Freudenberg R, Oehme L, Andreeff M, Wunderlich G, et al. Radiation exposure of patients during 68Ga-DOTATOC PET\/CT examinations. Nuklearmedizin. 2009;48(05):201\u20137.","journal-title":"Nuklearmedizin"},{"issue":"1","key":"2072_CR57","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00259-007-0587-y","volume":"35","author":"C Pettinato","year":"2008","unstructured":"Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35(1):72\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2072_CR58","first-page":"608","volume":"46","author":"G Brix","year":"2005","unstructured":"Brix G, Lechel U, Glatting G, Ziegler SI, M\u00fcnzing W, M\u00fcller SP, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET\/CT examinations. J Nucl Med. 2005;46(4):608\u201313.","journal-title":"J Nucl Med"},{"issue":"10","key":"2072_CR59","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1007\/s00259-010-1512-3","volume":"37","author":"I Virgolini","year":"2010","unstructured":"Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET\/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2072_CR60","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2967\/jnumed.116.185587","volume":"58","author":"M Barrio","year":"2017","unstructured":"Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, et al. The impact of somatostatin receptor-directed PET\/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis. J Nucl Med. 2017;58(5):756\u201361.","journal-title":"J Nucl Med"},{"issue":"11","key":"2072_CR61","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.3390\/cimb44110373","volume":"44","author":"G Poletto","year":"2022","unstructured":"Poletto G, Cecchin D, Sperti S, Filippi L, Realdon N, Evangelista L. Head-to-head comparison between peptide-based radiopharmaceutical for PET and SPECT in the evaluation of neuroendocrine tumors: a systematic review. Curr Issues Mol Biol. 2022;44(11):5516\u201330.","journal-title":"Curr Issues Mol Biol"},{"issue":"1","key":"2072_CR62","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40658-022-00487-7","volume":"9","author":"A Braune","year":"2022","unstructured":"Braune A, Oehme L, Freudenberg R, Hofheinz F, van den Hoff J, Kotzerke J, et al. Comparison of image quality and spatial resolution between 18F, 68Ga, and 64Cu phantom measurements using a digital biograph vision PET\/CT. EJNMMI Phys. 2022;9(1):58.","journal-title":"EJNMMI Phys"},{"issue":"3","key":"2072_CR63","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2967\/jnumed.116.180430","volume":"58","author":"CB Johnbeck","year":"2017","unstructured":"Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, et al. Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET\/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med. 2017;58(3):451\u20137.","journal-title":"J Nucl Med"},{"issue":"11","key":"2072_CR64","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s00259-019-04474-6","volume":"46","author":"K Goffin","year":"2019","unstructured":"Goffin K. Al18F-NOTA-octreotide and 18F-SiFAlin-TATE: two \u2018new kids on the block\u2019 in somatostatin receptor imaging. Eur J Nucl Med Mol Imaging. 2019;46(11):2225\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"2072_CR65","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00259-020-04918-4","volume":"47","author":"E Pauwels","year":"2020","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, et al. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020;47(13):3033\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"2072_CR66","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.3390\/diagnostics13132154","volume":"13","author":"A Adnan","year":"2023","unstructured":"Adnan A, Basu S. Somatostatin receptor targeted PET-CT and its role in the management and theranostics of gastroenteropancreatic neuroendocrine neoplasms. Diagnostics. 2023;13(13):2154.","journal-title":"Diagnostics"},{"issue":"17","key":"2072_CR67","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.3390\/molecules25174012","volume":"25","author":"R Eychenne","year":"2020","unstructured":"Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of radiolabeled somatostatin analogs for cancer imaging and therapy. Molecules. 2020;25(17):4012.","journal-title":"Molecules"},{"issue":"5","key":"2072_CR68","doi-asserted-by":"publisher","first-page":"682","DOI":"10.2967\/jnumed.123.265406","volume":"64","author":"A Imperiale","year":"2023","unstructured":"Imperiale A, Jha A, Meuter L, Nicolas GP, Ta\u00efeb D, Pacak K. The emergence of somatostatin antagonist-based theranostics: paving the road toward another success? J Nucl Med. 2023;64(5):682\u20134.","journal-title":"J Nucl Med"},{"issue":"3","key":"2072_CR69","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00259-018-4193-y","volume":"46","author":"S Krebs","year":"2019","unstructured":"Krebs S, Pandit-Taskar N, Reidy D, Beattie BJ, Lyashchenko SK, Lewis JS, et al. Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;46(3):677\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2072_CR70","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.122.264890","volume":"64","author":"Z Lin","year":"2023","unstructured":"Lin Z, Zhu W, Zhang J, Miao W, Yao S, Huo L. Head-to-head comparison of 68Ga-NODAGA-JR11 and 68Ga-DOTATATE PET\/CT in patients with metastatic, well-differentiated neuroendocrine tumors: interim analysis of a prospective bicenter study. J Nucl Med. 2023;64(9):1406\u201311.","journal-title":"J Nucl Med"},{"issue":"4","key":"2072_CR71","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","volume":"128","author":"DL Chan","year":"2023","unstructured":"Chan DL, Hayes AR, Karfis I, Conner A, Furtado O\u2019Mahony L, Mileva M, et al. Dual [68Ga]DOTATATE and [18F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score. Br J Cancer. 2023;128(4):549\u201355.","journal-title":"Br J Cancer"},{"issue":"1","key":"2072_CR72","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2967\/jnmt.116.185777","volume":"45","author":"N Sampathirao","year":"2017","unstructured":"Sampathirao N, Basu S. MIB-1 index-stratified assessment of dual-tracer PET\/CT with 68Ga-DOTATATE and 18F-FDG and multimodality anatomic imaging in metastatic neuroendocrine tumors of unknown primary in a PRRT workup setting. J Nucl Med Technol. 2017;45(1):34\u201341.","journal-title":"J Nucl Med Technol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02072-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02072-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02072-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:56:43Z","timestamp":1757206603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02072-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2072"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02072-1","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,28]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}